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on the role of fluoroquinolones in the management of
complicated urinary tract infections (cUTI), particularly in
countrieswith high rates (>20%) of fluoroquinolone-resistant
uropathogens. Pharmacokinetic/pharmacodynamic and
limited clinical data support the fact that specific fluo-
roquinolone breakpoints might be needed for UTI. Resistant
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might clinically respond to fluoroquinolone therapy.
The Taiwan Urinary Tract Infection Consensus Meeting
was held on September 18, 2010, in Taipei. A total of 12
infectious-disease specialists from 12 major teaching
hospitals located in different parts of Taiwan participated
in the meeting. The meeting aimed to attain consensus on
the role of fluoroquinolones in the management of UTI,ernal Medicine, National Taiwan University College of Medicine, 7
ished by Elsevier Taiwan LLC. All rights reserved.
Figure 2. Levofloxacin susceptibility rates among clinical
urinary isolates of Escherichia coli from 12 major teaching
hospitals in Taiwan from January to June 2010.
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roquinolone resistance among uropathogens.
Urinary tract infections are the most frequently occur-
ring bacterial infections in the community and in hospitals.
Trimethoprimesulfamethoxazole (SXT) is generally consid-
ered to be the drug of choice for the treatment of
uncomplicated UTI.1,2 However, the persistently high rates
(>20%) of SXT resistance among urinary Escherichia coli
isolates have made this agent unsuitable for empirical
treatment of UTI (Fig. 1).1e3 Several international guide-
lines recommend fluoroquinolones as the drugs of choice
for empirical treatment of UTI, including catheter-associ-
ated UTI.2,4e7 Levofloxacin 750 mg once daily for 5 days has
been shown to be as effective as ciprofloxacin 400 mg
(intravenous) or 500 mg (oral) twice daily for 10 days in the
treatment of adults with cUTI and acute pyelonephritis,
including patients with concurrent bacteremia.8,9 However,
the rapid emergence of fluoroquinolone-resistant E coli
(the most commonly encountered uropathogen) suggests
that further use would make fluoroquinolones unreliable for
treatment within the near future.10,11 Moreover, the
widespread use of fluoroquinolones for cUTI or catheter-
associated UTI might result in reduced susceptibility of
respiratory pathogens to these agents.1,10e12
Increasing resistance of uropathogens to fluoroquinolones
is of clinical concern. Rates of levofloxacin susceptibility of
clinical isolates of urinary E coli obtained from 12 major
teaching hospitals located in different parts of Taiwan
ranged from 70% to 80% (Fig. 2). In addition, recent studies
have found a rapid increase in levofloxacin resistance
among E coli isolates from patients treated in emergency
departments and outpatient clinics.10,11 Risk factors for
infections with levofloxacin-resistant E coli include recent
hospitalization and prior levofloxacin use.1,10,11 These risk
factors should be considered before initiating empirical
treatment with a fluoroquinolone for UTI.
However, the key controversy is that in vitro resistance
to fluoroquinolones can always translate into clinical failure
in patients with UTI, particularly when higher than regular
doses of fluoroquinolones (e.g. 750 mg levofloxacin) are
administered. Patients with UTI caused by SXT-resistant
pathogens have worse clinical outcomes than those infec-
ted with susceptible isolates.1,13 Nevertheless, in vitroFigure 1. Rates of nonsusceptibility to levofloxacin and
trimethoprim-sulfamethoxazole (SXT) among all clinical
urinary isolates in patients treated at the National Taiwan
University Hospital from 2004 to 2009.resistance to SXT translates into clinical failure in approx-
imately 50% of patients with community-acquired UTIs.1,13
The MIC breakpoints of trimethoprim or SXT for Enter-
obacteriaceae and staphylococci provided by the Clinical
and Laboratory Standards Institute were categorized only
for treating UTIs.14 Importantly, the Clinical and Laboratory
Standards Institute provides a urine-specific breakpoint
for some fluoroquinolones (lomefloxacin, ofloxacin, and
norfloxacin) but not for ciprofloxacin or levofloxacin for
Enterobacteriaceae and Pseudomonas aeruginosa.14
Although most of the clinical microbiology laboratories
determine the susceptibilities of urinary isolates of Enter-
obacteriaceae to levofloxacin and ciprofloxacin by applying
non-urine-specific MIC breakpoints, it does not mean that
levofloxacin and ciprofloxacin are not suitable for the
treatment of UTIs caused by pathogens with “in vitro
resistance” to these two agents.
Previous studies have clearly demonstrated that the
mean peak urinary concentrations of levofloxacin (0e1.5
hours) were 347 mg/mL at a dose of 500 mg and 620 mg/mL
at a dose of 750 mg.15e17 High-dose levofloxacin (750 mg)
exhibited early and prolonged (8e12 hours) urinary bacte-
ricidal activity against levofloxacin-resistant E coli isolates
(MIC range, 4e32 mg/mL) in virtually all subjects.15 Previous
studies also found that ciprofloxacin at standard doses or
ciprofloxacin XR (1,000 mg) once daily had prolonged
bactericidal activity in urine.18
Some reported clinical cases support those ex vivo
findings. Miller et al.19 reported a case in which cipro-
floxacin (500 mg twice daily) was an effective treatment for
cystitis because of a ciprofloxacin-resistant strain of E coli
(MICs> 4 mg/mL). In a clinical trial of levofloxacin (750 mg
once daily) versus ciprofloxacin (500 mg twice daily) for the
treatment of acute pyelonephritis, four patients were
infected with fluoroquinolone-resistant E coli isolates.8
Ciprofloxacin was effective at eradicating two of four
isolates, and levofloxacin was effective against another
isolate. The MIC values of ciprofloxacin were 8 mg/mL and
greater than 32 mg/mL, and the MIC value of levofloxacin
was 32 mg/mL.8
Additional susceptibility breakpoints for uropathogensmay
be warranted for selected fluoroquinolones.16,19 The suscep-
tibility concentration (4 mg/mL) in urine for norfloxacin is
approximately three times its peak serum level.14 A similar
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breakpoint in urine between 16 mg/mL and 32 mg/mL.16e18
Based on that assumption, more than 90% of E coli (MIC90,
16 mg/mL) causing cUTI in Japan and the E coli isolates [MIC90,
16 mg/mL; 29% were categorized as not susceptible to levo-
floxacin (MIC  4 mg/mL)] recovered in intensive care units in
Taiwan were susceptible to levofloxacin.16,20 Ciprofloxacin
exhibited a higher MIC90 (64 mg/mL) compared with levo-
floxacin, indicating a high rateof resistance of E coli isolates to
ciprofloxacin.20 The greater effect of the AcrAB, MdfA, and
NorE efflux pumps on ciprofloxacin compared with that on
levofloxacin inEcolimightpartlycontributetothisfinding.21,22
It is reasonable to consider a 5-day course of levo-
floxacin or a 10-day course of ciprofloxacindthough other
fluoroquinolones may be just as effective but have not been
evaluateddfor the treatment of cUTI or acute pyelone-
phritis if the causative uropathogen is susceptible.23
Moreover, in geographical areas in which more than 20%
of urinary E coli isolates are nonsusceptible to levofloxacin,
a high daily dose (750 mg) of levofloxacin might still be
useful for the empirical treatment of cUTI caused by E coli
isolates with MICs less than 32 mg/mL. The major caveat
with this higher susceptibility breakpoint for uropathogens
would be in patients who have severe cUTIs or urosepsis
with concurrent bacteremia.
In summary, pharmacokinetic/pharmacodynamic data
and limited clinical observation indicated that UTI caused
by isolates with relatively low MICs (e.g. 16 mg/mL) might
respond to fluoroquinolone therapy, and that specific fluo-
roquinolone breakpoints would be required for UTI.
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